Cagrilintide Semaglutide 2.4 2.4 Or 5 5 NuScience Peptides Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet 1 CagriSema 2.4 mg 2.4 mg FDA NDA filing; Novo Nordisk data on file., 2 Garvey WT, Blher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed Cagrilintide 5mg Peptide Puratek Peptides USA Novo Nordisk files for FDA approval for CagriSema, the first once weekly combination of GLP1 and amylin analogues